Skip to main
ELTX

ELTX Stock Forecast & Price Target

ELTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Elicio Therapeutics is expected to see continued success and growth in the coming years with its innovative immunotherapies targeting KRAS-mutated cancers. The company's impressive leadership, promising pipeline, and potential market size make it a strong contender in the competitive biotechnology industry. However, careful evaluation of clinical trial data and the ever-evolving nature of oncology treatments should be considered when making investment decisions.

Bears say

Elicio Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies for the treatment of cancer, with a focus on mKRAS-positive pancreatic cancer, CRC, lung cancer, and other mKRAS-positive cancers. While their proprietary AMP technology has shown some early promise in terms of biomarker reduction and immune response, the company is still in the early stages of clinical development and the Phase 2 trial design raises some concerns. Additionally, their market opportunity seems limited, as there are already approved targeted therapies for mKRAS-positive cancers.

ELTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elicio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elicio Therapeutics Inc (ELTX) Forecast

Analysts have given ELTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, ELTX has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elicio Therapeutics Inc (ELTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.